TNFRSF17 Protein (C-His, Human)

1.Flow cytometric analysis of anti-BCMA CAR expression. 5e5 of anti-BCMA CAR-293 cells were stained with 100 μL of 1:125 dilution of APC-conjugated human BCMA protein (Site-Specific APC Conjugation, ECD, His Tag, Cat. No. 10620-H86H-SA) and negative control protein. Non-transduced 293 cells were used as a control (left) . APC signal was used to evaluate the binding activity (QC tested) . 2.Binding activity of APC-conjugated BCMA protein to PBMC cells. PBMC cells were stained with FITC conjugated anti-CD3 antibody and APC-conjugated human BCMA protein (Site-Specific APC Conjugation, ECD, His Tag, Cat. No. 10620-H86H-SA) and detected by flow cytometry. FITC signal was used to evaluate the content of CD3+ T cells in PBMCs. APC signal was used to evaluate the non-specific binding activity to PBMCs (QC tested) . 3.Flow cytometric analysis using APC conjugated BCMA protein. 5e5 of anti-BCMA CAR-293 cells were stained with APC-conjugated human BCMA protein (Site-Specific APC Conjugation, ECD, His Tag, Cat. No. 10620-H86H-SA) . Non-transduced 293 cells were used as a control (Black Histogram) . The protein exhibited stable performance after multiple freeze-thaw cycles (10 cycles) . 4.Flow cytometric analysis using APC conjugated BCMA protein. 5e5 of anti-BCMA CAR-293 cells were stained with APC-conjugated human BCMA protein from two vendors (competitor A and SINO) . Non-transduced 293 cells were used as a control (Black Histogram) . The results demonstrated that SINO’s 10620-H86H-SA has a higher fluorescence intensity than that of the competitor.